2015
Bioabsorbable polymer‐coated sirolimus‐eluting stent implantation preserves coronary vasomotion: A DESSOLVE II trial sub‐study
Rusinaru D, Vrolix M, Verheye S, Chowdhary S, Schoors D, Di Mario C, Desmet W, Donohoe DJ, Ormiston JA, Knape C, Bezerra H, Lansky A, Wijns W, Investigators O. Bioabsorbable polymer‐coated sirolimus‐eluting stent implantation preserves coronary vasomotion: A DESSOLVE II trial sub‐study. Catheterization And Cardiovascular Interventions 2015, 86: 1141-1150. PMID: 25044635, DOI: 10.1002/ccd.25610.Peer-Reviewed Original ResearchMeSH KeywordsAbsorbable ImplantsAgedCardiac Pacing, ArtificialCardiovascular AgentsCoronary AngiographyCoronary Artery DiseaseCoronary VesselsDrug-Eluting StentsEuropeFemaleHistorically Controlled StudyHumansMaleMiddle AgedNew ZealandPercutaneous Coronary InterventionPolymersProspective StudiesSingle-Blind MethodSirolimusTime FactorsTreatment OutcomeVasoconstrictionVasodilationConceptsZotarolimus-eluting stentsDrug-eluting stentsCoronary vasomotionII trialVasomotor dysfunctionFirst-generation drug-eluting stentsEndeavor zotarolimus-eluting stentsGeneration drug-eluting stentsCoronary vasomotor dysfunctionSirolimus-eluting stentsQuantitative coronary angiographyVessel diameterMaximal pacingCoronary angiographyZES groupCoronary arteryVasomotor responsesHistorical groupStent edgeNormal vasomotionPatientsPercent changeReference segmentsVasomotionSES group
2014
First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31 379 patients
Navarese EP, Kowalewski M, Kandzari D, Lansky A, Górny B, Kołtowski Ł, Waksman R, Berti S, Musumeci G, Limbruno U, van der Schaaf RJ, Kelm M, Kubica J, Suryapranata H. First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31 379 patients. Open Heart 2014, 1: e000064. PMID: 25332803, PMCID: PMC4189321, DOI: 10.1136/openhrt-2014-000064.Peer-Reviewed Original ResearchSecond-generation drug-eluting stentsPaclitaxel-eluting stentsDrug-eluting stentsSecond-generation EESCoronary artery diseaseMyocardial infarctionEnd pointArtery diseaseClinical trialsPrespecified safety end pointsStable coronary artery diseaseIncidence of MIFirst-generation drug-eluting stentsFirst-generation SESReduction of oddsEfficacy end pointSafety end pointTarget lesion revascularisationAcute coronary syndromeComposite end pointSafe drug-eluting stentCurrent clinical practiceLong-term safetyVessel revascularisationCardiac mortality
2012
Mid-term results of everolimus-eluting stent in a Japanese population compared with a US randomized cohort: SPIRIT III Japan Registry with harmonization by doing.
Saito S, Nakamura S, Fujii K, Nakamura M, Isshiki T, Hirayama H, Kikuchi T, Fujita H, Nonogi H, Mitsudo K, Kimura T, Igarashi K, Saito K, Lansky AJ, Stone GW, Honda Y, Waseda K, Fitzgerald PJ, Sudhir K. Mid-term results of everolimus-eluting stent in a Japanese population compared with a US randomized cohort: SPIRIT III Japan Registry with harmonization by doing. Journal Of Invasive Cardiology 2012, 24: 444-50. PMID: 22954564.Peer-Reviewed Original ResearchConceptsMajor adverse cardiac eventsPaclitaxel-eluting stentsDrug-eluting stentsSegment late lossJapan RegistryLate lossUS patientsEES groupPrimary endpointSingle-arm multicenter studySecond-generation drug-eluting stentsFirst-generation drug-eluting stentsLower late lossTarget vessel failureAdverse cardiac eventsMid-term resultsCardiac eventsPES groupMulticenter studyJapanese patientsNeointimal volumeApposition ratePatientsStudy aimClinical programsFirst report of a novel abluminal groove filled biodegradable polymer rapamycin-eluting stent in de novo coronary artery disease: results of the first in man FIREHAWK trial.
Qian J, Xu B, Lansky AJ, Yang YJ, Qiao SB, Wu YJ, Chen J, Hu FH, Yang WX, Mintz GS, Leon MB, Gao RL. First report of a novel abluminal groove filled biodegradable polymer rapamycin-eluting stent in de novo coronary artery disease: results of the first in man FIREHAWK trial. Chinese Medical Journal 2012, 125: 970-6. PMID: 22613516.Peer-Reviewed Original ResearchConceptsMajor adverse cardiac eventsQuantitative coronary angiographyDrug-eluting stentsAbluminal grooveMyocardial infarctionDe novo coronary artery diseaseDe novo native coronary stenosisIschemia-driven target lesion revascularizationNovo coronary artery diseaseStent late lumen lossFirst-generation drug-eluting stentsComplete strut coverageAdverse cardiac eventsTarget lesion revascularizationTarget vessel revascularizationClinical success rateCoronary artery diseaseLate lumen lossNative coronary stenosisPrior myocardial infarctionStent late lossLate DES thrombosisLong-term restenosisLesion revascularizationPrimary endpoint